Implementation of corticosteroid pre-treatment and close monitoring with dose adjustments according to myelosuppression, liver function abnormalities, and CPK levels have contributed to a reduction in the incidence of rhabdomyolysis and are currently included in the guidelines for trabectedin administration. This evidence concerns the gene PIK3C2A and rhabdomyolysis.